Autopsy report · NCT04847583

A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

“Sponsor's Decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 6 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Qurient Co., Ltd.

Sponsor type

Industry

Conditions

COVID-19 Virus Infection

Interventions

Telacebec; COVID-19 Standard of care

Participants

1

Sites

3

Countries

South Africa

Trials that died the same way

• Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
  “Sponsor Decision” (98% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.